Federal Regulations of Cannabis for Public Health in the United States

Millions of Americans use cannabis in moderation each month without any problems. However, evidence is mounting of harmful physical and mental health effects associated with heavy or long-term regular cannabis use. At the same time, existing legal markets in the United States are making high-potency cannabis products available to adult consumers. Recent international recommendations suggest that governments adopt market regulations that promote responsible use. Federal policymakers in the U.S. are debating liberalizing cannabis policy and looking to states and nations with existing recreational cannabis laws as examples. Amid this debate, it is important to examine the extent to which regulations within various jurisdictions promote responsible use and protect public health. We review elements of cannabis legalization policies across U.S. states, Canada and Uruguay that research suggests could be important for promoting responsible use. Specific policy areas considered include: capping the amount of delta-9-tetrahydrocannabinol (THC) in all products, instituting sales limits, taxing cannabis based on potency of THC and implementing seed-to-sale tracking systems. We find that current regulations of legal cannabis markets are weaker in the U.S. compared to Canada and Uruguay in terms of preventing harmful use across these dimensions. Federal policymakers should understand the strengths and limitations of existing U.S. state policies and consider public health regulations being adopted abroad when developing federal cannabis regulations.

You can read the full study published in the Schaeffer Center White Paper Series here: https://healthpolicy.usc.edu/research/federal-regulations-of-cannabis-for-public-health-in-the-u-s/

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.5

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents: Impacts of Maternal Cannabis Use on Long-Term Psychiatric Risk

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Medical marijuana access and prolonged opioid use among adolescents and young adults

Abstract Background and Objectives Laws liberalizing access to medical marijuana are associated with reduced opioid analgesic use among adults, but little is known about the impact of such policies on adolescents and young adults. Methods This retrospective cohort study used 2005 to 2014 claims from MarketScan® Commercial database, which covers all 50 states and Washington

Scroll to Top